Roche Holding AG made the company’s second major gene therapy deal in a year, spending $1.15 billion to obtain the rights to Sarepta Therapeutics Inc.’s investigational drug to treat duchenne muscular dystrophy (DMD) outside the United States.

Wave Life Sciences Ltd. announced the formation of a global strategic collaboration with Takeda Pharmaceutical Company Ltd. to discover, develop and commercialize nucleic acid therapies for disorders of the central nervous system.